CMBT vs CSAN

CMBT presents a contradictory profile: explosive revenue growth (160% YoY) paired with a deteriorating earnings track record and poor liquidity. While the Piotroski F-Score of 6/9 indicates stable financial health, the company has missed earnings estimates in 4 consecutive quarters with a severe average surprise of -156.54%. The stock trades slightly above its Graham Number ($11.93) and significantly above its growth-based intrinsic value ($4.90), suggesting a valuation premium that is not currently supported by bottom-line performance. High leverage (Debt/Equity 2.12) and a current ratio below 1.0 create a precarious financial position despite strong operating margins.

CSAN exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 2/9, indicating weak fundamental health. While the company maintains strong liquidity (Current Ratio 2.58) and impressive operating margins (30.71%), these are completely offset by a negative net profit margin of -24.05% and a catastrophic YoY EPS decline of -712.5%. The stock is in a long-term technical downtrend, losing over 72% of its value over five years, and consistently misses earnings estimates. Despite a low Price/Sales ratio, the negative ROE and poor earnings quality make the current valuation risky.